Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Sutro Biopharma's Operating Leases history runs 5 years deep, the most recent figure standing at $7.9 million for Q4 2025.

• In Q4 2025, Operating Leases fell 49.66% year-over-year to $7.9 million; the TTM figure through Dec 2025 stood at $7.9 million (down 49.66% YoY), while the FY2025 annual figure was $7.9 million, down 49.66% from the prior year.
• Operating Leases came in at $7.9 million for Q4 2025 at Sutro Biopharma, down from $9.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $32.1 million in Q3 2021 to a low of $7.9 million in Q4 2025.
• A 5-year average of $22.6 million and a median of $24.0 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases decreased 3.23% in 2022 and tumbled 49.66% in 2025, its largest moves.
• Sutro Biopharma's Operating Leases stood at $31.2 million in 2021, then decreased by 5.28% to $29.6 million in 2022, then decreased by 21.71% to $23.2 million in 2023, then sank by 32.31% to $15.7 million in 2024, then sank by 49.66% to $7.9 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $7.9 million, $9.7 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison